Therapeutic antibodies
View Patent ↗A pharmaceutical comprising a therapeutic protein that hinds to a therapeutic target, the protein being modified with a compound that inhibits binding of the protein to the therapeutic target, the modified protein being effective for reducing an immune response against the protein and for producing a therapeutic effect by binding to the therapeutic target. The therapeutic protein may be an antibody that includes an antibody combining site that binds to the therapeutic target.
1. A process for treating lymphoma or marrow transplant rejection or organ transplant rejection or an autoimmune disease in a mammal, comprising: administering to said mammal a composition comprising (a) an isolated antibody which binds to CD52, said antibody including a light chain, said light chain consisting essentially of amino acid residues 33 through 263 of SEQ ID No: 1; and (b) a pharmaceutically acceptable carrier.
2. The process of claim 1 wherein the antibody is an aglycosylated antibody.
3. The process of claim 2 wherein the Fc portion of the antibody is aglycosylated.
4. The process of claim 1 wherein the antibody does not bind to the Fc receptor.